Physician profile
Ingrid Brown
NPI 1710516877
$6,043.47
in general payments reported to CMS, 2019-2025
24 companies · $1,604 in 2025
The $1,604 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $732 · 2023: $1,726 · 2024: $1,981 · 2025: $1,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,041 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,041.11 |
| Education | $270.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $903.40 | 2022-2025 | |
| Abbvie INC. | $841.93 | 2022-2025 | |
| Janssen Biotech, INC. | $782.92 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| E.R. Squibb & Sons, L.L.C. | $566.30 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $532.64 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $402.19 | 2022-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $263.42 | 2022-2025 | Nemluvio, Aklief |
| Amgen INC. | $250.12 | 2023-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $222.07 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $192.56 | 2022-2025 | Winlevi |
| Ucb, INC. | $189.11 | 2022-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $147.19 | 2022-2025 | Libtayo, Dupixent |
| Genzyme Corporation | $136.63 | 2022-2025 | |
| Pfizer INC. | $118.14 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $103.16 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $77.65 | 2023-2025 | Zoryve |
| Organon LLC | $65.40 | 2024-2025 | Vtama |
| Incyte Corporation | $57.18 | 2022 | |
| Journey Medical Corporation | $47.50 | 2023-2025 | |
| Sebela Pharmaceuticals INC. | $47.16 | 2023 | Naftin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.63 | 2024 | Spevigo |
| Verrica Pharmaceuticals INC. | $31.57 | 2024 | Ycanth |
| Genentech, INC. | $17.99 | 2023 | Erivedge |
| Sandoz INC. | $14.61 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.